| 2026-10-22 17:20 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Clinical updates and media appearances; no M&A signals detected. |
SEC · detail |
| 2026-10-15 16:30 |
8-K |
["5.02", "7.01", "9.01"] |
officer change |
0.35
|
Director resignation and appointment of banking executive from UAE; weak M&A signal absent strategic review or transaction language. |
SEC · detail |
| 2026-09-28 17:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
FDA meeting announcement for NEO212 drug candidate; no M&A signals present. |
SEC · detail |
| 2026-09-21 16:30 |
8-K |
["3.03", "5.03", "7.01", "9.01"] |
other |
0.05
|
Redemption of Series A Preferred Stock; no M&A signals detected. |
SEC · detail |
| 2026-09-17 06:02 |
8-K |
["7.01", "9.01"] |
other |
0.15
|
CEO open-market stock purchase; no M&A signal. Routine insider buying disclosure. |
SEC · detail |
| 2026-09-10 10:27 |
8-K |
["1.01"] |
other |
0.05
|
Registered direct offering of common stock and warrants for working capital and preferred stock redemption; no M&A signal. |
SEC · detail |
| 2026-08-21 14:58 |
8-K |
["5.02"] |
other |
0.05
|
Routine board committee assignment amendment; no M&A signal. |
SEC · detail |
| 2026-08-20 09:00 |
8-K |
["5.07"] |
other |
0.00
|
Routine annual stockholder meeting voting results; no M&A signals present. |
SEC · detail |
| 2026-08-13 17:21 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine investor conference call disclosure on clinical trial results; no M&A signals present. |
SEC · detail |
| 2026-08-12 08:30 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
8-K discloses Phase 2a clinical trial results and investor presentation; no M&A signals. |
SEC · detail |
| 2026-08-10 17:15 |
8-K |
["2.02", "7.01", "9.01"] |
other |
0.05
|
Routine 8-K reporting Q2 financial results and Phase 2a clinical trial presentation; no M&A signals. |
SEC · detail |
| 2026-07-15 09:15 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
FDA feedback on drug development program; no M&A indicators present. |
SEC · detail |
| 2026-07-02 17:11 |
8-K |
["5.02"] |
officer change |
0.15
|
Director resignation and replacement with strategy executive; no M&A language or indicators present. |
SEC · detail |
| 2026-06-23 17:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Regulatory approval announcement for drug candidate; no M&A signals present. |
SEC · detail |
| 2026-06-18 17:00 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Regulatory approval announcement for drug candidate; no M&A activity indicated. |
SEC · detail |
| 2026-06-12 06:01 |
8-K |
["1.01", "3.02", "3.03"] |
other |
0.05
|
Series A convertible preferred stock private placement; no M&A, activist, or strategic transaction indicators. |
SEC · detail |
| 2026-05-18 17:00 |
8-K |
["2.02", "7.01", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings release with no M&A-related content or strategic transaction indicators. |
SEC · detail |
| 2026-04-24 17:00 |
8-K |
["1.01", "3.02", "9.01"] |
other |
0.05
|
Multiple securities purchase agreements for equity financing; no M&A or activist transaction signals. |
SEC · detail |